^
24d
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
Photofrin (porfimer sodium)
5ms
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jun 2025 --> Dec 2025
Trial completion date
|
Photofrin (porfimer sodium)
8ms
Trial completion date
|
Photofrin (porfimer sodium)
9ms
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
P1/2, N=19, Terminated, Roswell Park Cancer Institute | Trial completion date: Feb 2030 --> Jul 2024 | Active, not recruiting --> Terminated; was paused by device company for a long period of time
Trial completion date • Trial termination
|
Photofrin (porfimer sodium)
12ms
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov)
P1, N=5, Terminated, Roswell Park Cancer Institute | Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Nov 2023 --> Oct 2024
Trial completion date • Trial primary completion date
|
Opdivo (nivolumab) • Photofrin (porfimer sodium)
1year
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Recruiting --> Active, not recruiting | N=102 --> 52
Enrollment closed • Enrollment change
|
Photofrin (porfimer sodium)
1year
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Nov 2023 --> Jul 2024
Trial primary completion date • Endobronchial ultrasound • Metastases
|
Photofrin (porfimer sodium)
1year
Trial termination • Metastases
|
Opdivo (nivolumab) • Photofrin (porfimer sodium)
1year
Enrollment closed • Enrollment change • Metastases
|
Opdivo (nivolumab) • Photofrin (porfimer sodium)
over1year
Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (clinicaltrials.gov)
P1, N=5, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=16 --> 5 | Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Mar 2025 --> Feb 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Photofrin (porfimer sodium)
over1year
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
P2, N=102, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
Photofrin (porfimer sodium)
over1year
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=65 --> 19 | Trial primary completion date: Feb 2030 --> Nov 2023
Enrollment closed • Enrollment change • Trial primary completion date • Endobronchial ultrasound • Metastases
|
Photofrin (porfimer sodium)